secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001437749-25-029347
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia CardiAMP trial roll-in cohort shows +80 sec exercise tolerance, 82% fewer angina episodes at 6 months
--------------------------------------------------------------------------------

- Open-label roll-in cohort (N not given) met primary endpoint; no treatment-emergent major adverse cardiac events.
- Average exercise tolerance improved by 80 seconds at six-month follow-up vs. pre-treatment.
- Angina episodes reduced by an average of 82% at the six-month primary endpoint.
- 60% of patients showed substantial improvement in both exercise tolerance and angina reduction.
- Results compare favorably to FDA-approved therapies Ranolazine and EECP; data to be submitted for peer review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925029347/0001437749-25-029347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925029347/bcda20250917_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer